Cantor Fitzgerald Raises Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target to $46.00

Key Points

• Cantor Fitzgerald has increased its target price for Supernus Pharmaceuticals from $42.00 to $46.00, indicating a potential upside of 9.54% from the stock's previous close.
• Supernus Pharmaceuticals stocks surged 11.9% during trading hours, reaching $41.99, with over 1 million shares exchanged.
• Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating, reflecting increased confidence in the company's prospects.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) had its target price boosted by investment analysts at Cantor Fitzgerald from $42.00 to $46.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the specialty pharmaceutical company's stock. Cantor Fitzgerald's target price would suggest a potential upside of 11.73% from the company's previous close.

Separately, Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock traded down $0.29 during midday trading on Wednesday, reaching $41.17. The company's stock had a trading volume of 244,834 shares, compared to its average volume of 623,088. The firm has a market capitalization of $2.31 billion, a PE ratio of 35.80 and a beta of 0.74. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $43.62. The stock's 50 day simple moving average is $33.24 and its 200 day simple moving average is $33.45.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SUPN. Armistice Capital LLC raised its position in Supernus Pharmaceuticals by 7.4% during the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock worth $170,169,000 after acquiring an additional 360,000 shares during the last quarter. Geode Capital Management LLC increased its position in Supernus Pharmaceuticals by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after buying an additional 28,517 shares in the last quarter. GW&K Investment Management LLC lifted its position in shares of Supernus Pharmaceuticals by 14.6% in the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after acquiring an additional 176,091 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Supernus Pharmaceuticals by 18.3% during the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after purchasing an additional 110,867 shares during the last quarter. Finally, Ashford Capital Management Inc. grew its stake in Supernus Pharmaceuticals by 3.8% in the 1st quarter. Ashford Capital Management Inc. now owns 566,556 shares of the specialty pharmaceutical company's stock worth $18,555,000 after acquiring an additional 20,781 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.